Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 11/20 | 0.54 |
| ▸ | CTRC | Q99895 | 7/20 | 0.54 |
| ▸ | CMA1 | P23946 | 7/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5728160 | 1.00 | ELANE (0.54) | ELANECTRCCMA1CASP1 | |
| SCHEMBL6110034 | 0.91 | ELANE (0.57) | ELANECTRCCMA1 | |
| SCHEMBL6110027 | 0.91 | ELANE (0.57) | ELANECTRCCMA1 | |
| SCHEMBL6555937 | 0.88 | CTRC (0.70) | ELANECTRCCMA1 | |
| Hydrochloric Acid SCHEMBL5728980 | 0.85 | CMA1 (0.68) | CTRCCMA1 | |
| Hydrochloric Acid SCHEMBL5728984 | 0.85 | CMA1 (0.68) | CTRCCMA1 | |
| SCHEMBL5728765 | 0.82 | ELANE (0.55) | ELANECTRCCMA1CASP1 | |
| SCHEMBL5728626 | 0.81 | ELANE (0.71) | ELANE | |
| SCHEMBL5728623 | 0.81 | ELANE (0.71) | ELANE | |
| SCHEMBL6710145 | 0.80 | ELANE (0.47) | ELANECTRCCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270850-A1 | Processes for preparation of pyrimidine derivatives and intermediates | AJINOMOTO CO., INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1695967-A1 | PROCESSES FOR PRODUCTION OF PYRIMIDINE DERIVATIVES AND INTERMEDIATES | Ajinomoto Co., Inc. (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050176966-A1 | Process for the preparation of pyrimidine derivative, intermediate therefor and process for the preparation thereof | AJINOMOTO CO., INC. (JP) | 2005-08-11 | — | — | US | disclosed |
| EP-1529778-A1 | Production method of pyrimidine derivative, intermediate therefor | Ajinomoto Co., Inc. (JP) | 2005-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176966-A1 | Process for the preparation of pyrimidine derivative, intermediate therefor and process for the preparation thereof | DPYD, WEE1, DCXR | ELANE 4520/4885CTRC 752/4885CMA1 1206/4885 |
| US-20060270850-A1 | Processes for preparation of pyrimidine derivatives and intermediates | PDXK, RNASEL, DPYD | ELANE 4219/4885CTRC 244/4885CMA1 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.